Shopping Cart
Remove All
Your shopping cart is currently empty
DNDI-VL-2098
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T218656 Copy Product Info
🥰Excellent
DNDI-VL-2098 is an orally active antileishmanial agent known for its high permeability and in vitro metabolic stability. It selectively inhibits CYP2C19 with an IC50 of 0.47 μM and does not affect other major CYP enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A4) at concentrations up to 12.5 μM. The compound exhibits favorable pharmacokinetic properties across various animal models including mice, hamsters, rats, and dogs. DNDI-VL-2098 is characterized by moderate to high plasma protein binding, making it suitable for visceral leishmaniasis research.
DNDI-VL-2098
Cas No. 681492-17-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | DNDI-VL-2098 is an orally active antileishmanial agent known for its high permeability and in vitro metabolic stability. It selectively inhibits CYP2C19 with an IC50 of 0.47 μM and does not affect other major CYP enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A4) at concentrations up to 12.5 μM. The compound exhibits favorable pharmacokinetic properties across various animal models including mice, hamsters, rats, and dogs. DNDI-VL-2098 is characterized by moderate to high plasma protein binding, making it suitable for visceral leishmaniasis research. |
| Targets & IC50 | CYP2C19:0.47 μM |
| In vitro | DNDI-VL-2098 (0.3-30 μg/mL; 4 h) exhibits moderate to high plasma protein binding rates (94-98%) with a free fraction of 3-6% in samples from mice, rats, dogs, and humans. It shows potent activity in an amastigote macrophage model with an IC50 of 0.025 μM against antimony-resistant Leishmania donovani DD8 strains and an IC50 of 0.7-2.6 μM against African clinical isolates. |
| In vivo | DNDI-VL-2098, when administered at a dose of 50 mg/kg orally once daily for five consecutive days, achieved over 99% parasite inhibition in an acute visceral leishmaniasis mouse model. In a chronic visceral leishmaniasis hamster model, DNDI-VL-2098 at 25 mg/kg demonstrated more than 85% parasite inhibition, showing superior efficacy compared to its racemic mixture and (S)-enantiomer. |
| Molecular Weight | 359.26 |
| Formula | C14H12F3N3O5 |
| Cas No. | 681492-17-1 |
| Smiles | C(OC1=CC=C(OC(F)(F)F)C=C1)[C@]2(C)OC=3N(C2)C=C(N(=O)=O)N3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: DNDI-VL-2098 in vivo | DNDI-VL-2098 in vitro | DNDI-VL-2098 formula | DNDI-VL-2098 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.